It was observed that there were 2.15, 1.21, and 1.85 greater risks of dying in patients diagnosed with CC (A), HNSC (B), and rectal cancer (C), when they express high levels of HIF1A, respectively, compared to patients with low levels of HIF1A expression. This evidence concerns the gene HIF1A and rectal cancer.